Clinical Trial Update: Bipolar Androgen Therapy + Carboplatin in mCRPC [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating bipolar androgen therapy in combination with carboplatin for castration-resistant prostate cancer, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• Bipolar androgen therapy
• CARBOPLATIN (Carboplatin)

Snippet

Sponsor: St Vincent's Hospital, Sydney | Conditions: Castration-resistant Prostate Cancer, Homologous Recombination Deficiency | Phase 2 | Status: RECRUITING